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Mycobacterium marinum infections 
in Denmark from 2004 to 2017: A 
retrospective study of incidence, 
patient characteristics, treatment 
regimens and outcome
Inge K. Holden1, Michala Kehrer1, Aase B. Andersen2, Christian Wejse3, Erik Svensson  4 &  
Isik Somuncu Johansen1
Mycobacterium marinum (M. marinum) is a slowly growing nontuberculous mycobacterium. The 
incidence of M. marinum infections in Denmark is unknown. We conducted a retrospective nationwide 
study including all culture confirmed cases of M. marinum from 2004 to 2017 in Denmark. All available 
medical records were reviewed. Demographics, clinical characteristics, and treatment regiments were 
analyzed. Fifty-five patients were identified, 40 (72.7%) were men with a median age of 50 years. 
Aquatic exposure was reported by 48 (90.6%) of the patients. Site of infection was upper extremities 
in 49 (92.5%) patients and 49 (92.5%) had superficial infection. The median time from symptom 
presentation to diagnosis was 194 days. All patients received antibiotics. Median time of treatment 
duration among all patients was 112 days. Treatment outcome was classified as improved in 40 (75%), 
improved with sequela in 4 (7.6%) patients and only 3 patients (3.8%) were classified as failed. Infection 
with M. marinum is rare and there is a long delay from symptom manifestation to diagnosis. The 
infection is predominantly related to aquatic exposure. M. marinum should be a differential diagnose 
in patients with slow-developing cutaneous elements and relevant exposure. Treatment outcomes are 
overall good and severe sequela are rare.
Mycobacterium marinum (M. marinum) is a slowly growing nontuberculous mycobacterium, which was first iso-
lated from marine fish. M. marinum is found in non-disinfected salt- and freshwater reservoirs such as swimming 
pools and fish tanks1,2. The bacteria may cause infections in humans when contaminated water or infected fish or 
seafood come in contact with skin lesions3.
Most infections with M. marinum are superficial skin infections characterized by granuloma and lymphang-
itis also known as “fish tank granuloma” or “swimming pool granuloma”; however, the infection may spread to 
deeper tissue causing tendinitis, arthritis and osteomyelitis3.
The incidence of M. marinum infections in Denmark is unknown. In France in 1996–1998, the incidence 
was reported to be 0.04 per 100 000 person years4. Recent studies from The United States reported an increase 
in incidence of cutaneous nontuberculous mycobacterial infections and M. marinum infections in particular1,5.
The treatment of M. marinum infection is long-term antibiotic treatment and in the more severe cases surgery 
may be needed1,5,6. The optimal duration of antibiotic treatment is not known; as little as four weeks of antibiotic 
treatment has been reported as successful but often the treatment duration will be extended to several months6–15.
This study was conducted to provide information regarding the incidence, clinical features, treatment regi-
mens and clinical outcome of patients infected with M. marinum infections in Denmark.
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Methods
We conducted a nationwide retrospective study in Denmark from January 1st, 2004 to May 31st, 2017.
All patients with a positive culture of M. marinum were included. Patients were followed from the time of 
registration of microbiological material at International Reference Laboratory of Mycobacteriology until the end 
of treatment, lost to follow-up, or May 31st, 2017, whichever came first.
The International Reference Laboratory of Mycobacteriology (IRLM) at Statens Serum Institut (SSI) is the 
only laboratory which performs all cultures, culture-based drug susceptibility testing, and molecular typing of M. 
tuberculosis complex and nontuberculous mycobacteria in Denmark16.
Cultures were performed in Mycobacterium Growth Indicator Tube system (MGIT; Becton Dickinson, 
Sparks, MD) and on Loewenstein- Jensen (LJ) incubated at 35 °C. For skin specimens and specimens for which 
M. marinum culture was requested, a supplemental LJ tube was inoculated and incubated in 33 °C. M. marinum 
was identified with nucleic acid techniques varying over the study period. Microscopy for acid-fast bacilli (AFB) 
using auramine-rhodamine stain were performed on all specimens.
We retrieved data from the laboratory register at IRLM on patients with positive M. marinum culture in the 
study period. M. marinum cases were cross-linked with administrative and medical registers using the unique 
Danish civil registration number, which is assigned to all residents of Denmark at birth or after residing legally 
in Denmark for 3 months. Medical records were reviewed for the following variables: age, sex, immunocompro-
mised status (HIV, organ transplantation, chronic corticosteroid use or other immunosuppressive drug use, or 
other immunocompromised condition (i.e. inflammatory bowel disease, rheumatoid arthritis)), history of aquatic 
exposure and type, localization and severity of infection (cutaneous or subcutaneous infections, ulcerations, nod-
uli, lymphangitis, tenosynovitis, arthritis, and osteomyelitis), time of onset of symptoms, diagnostic methods, any 
radiographic findings, perioperative findings, antibiotic treatment (type, duration, and cause of treatment change 
as well as having received empiric antibiotics prior to diagnosis), outcome and date of last registered contact.
The time to diagnosis was defined as the time from onset of symptoms to diagnosis of M. marinum infection 
by microscopy or culture.
Infection severity was classified into four clinical categories17,18: localized superficial cutaneous lesions (type 
I), nodular lymphangitis or with nodules, abscesses and granulomas (type II), deeper infections with or without 
skin involvement (type III), and disseminated infection (type IV).
In accordance with previous definitions, four treatment outcomes were defined: (a) “improved” if no recur-
rence of disease after cessation of antibiotic treatment, (b) “improved with morbidity” if sign of improvement but 
without return of full function of the affected limb, (c) “failed” if there was recurrence of disease after cessation 
of antibiotic treatment or persistence of disease despite ongoing therapy at time of last contact, and (d) “lost to 
follow-up” if no documentation of outcome or treatment in medical records7.
The initial antibiotic treatment regimen was defined as the first treatment regimen that was prescribed, while 
backbone antibiotic regimen was defined as the regimen used for the majority of the treatment period7.
Surgery was defined as having any surgery besides biopsy or aspiration.
Ethics. This study was approved by the Danish Data Protection Agency (Jnr. 16/13130 and 2012-54-0100) 
and the Danish Health Authority (Jnr 3-3013-1640/1). In accordance with Danish law, observational studies 
performed in Denmark do not need approval from the Medical Ethics Committee or written consent from par-
ticipants. All analyses are presented anonymously.
Analyses. All cases were included in the incidence rate analyses, but only cases with available medical records 
were used in the following analyses.
Continuous variables were described using medians with interquartile range (IQR), and categorical variables 
were described using frequency counts and percentages.
When appropriate, differences between categories were analyzed using the t test for qualitative values. 
Comparisons were made using the Student’s t-test, and a p-value of <0.05 was considered statistically significant.
The yearly population of Denmark on July 1 came from Statistics Denmark19. The population was defined as 
contributing to 1 person year per resident per year in the incidence rate analyses. The crude annual incidence 
rates were calculated as the number of incident cases per 100 000 person years with the corresponding 95% con-
fidence intervals (95% CI).
The statistical analyses were performed using Stata® (StataCorp., College Station, TX, USA, version 15.0).
Results
From January 1st, 2004 to May 31st, 2017, we identified 55 patients with culture verified M. marinum infections. 
No medical records were available for 2 patients, both treated in non-hospital settings.
The incidence rates are shown in Fig. 1. The incidence rate during 2004 to 2009 was 0.04–0.06 per 100 000 
person-years, from 2010 to 2016 the incidence rate was 0.05–0.13 per 100 000 person-years.
In total, 38 (71.7%) of the patients were men and the median age was 49 years (IQR: 36–59). The general 
patient characteristics, comorbidity and clinical findings are listed in Table 1. Almost all patients had a history of 
aquatic exposure (90.6%), the most common exposure came from maintenance of fish tanks. For the remaining 5 
patients, the exposure was unknown. Type I infection was the most frequent (66%) and finger/hand (88.7%) was 
the most common site of infection.
The median time from symptom presentation to diagnosis was 194 days (IQR: 80–548). A total of 21 patients 
received empiric antibiotic therapy, 9 patients received a regimen which was effective against M. marinum infec-
tion, 6 patient received beta-lactam antibiotics, and 1 patient received dapsone. For the remaining patients, infor-
mation regarding the empiric antibiotic regimen was not accessible.
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The incubation period could not be assessed since time of initial infection was unknown for the majority of 
the patients.
Treatment regimens and duration. The treatment regimens and median duration are listed in Table 2.
All patients were treated with antibiotics either as monotherapy (45.3%) or as a combination of up to four 
antibiotics. Only 6 patients (11.3%) needed surgery performed.
All patients were treated by specialists in dermatology, infectious diseases, or pulmonary diseases. Only 11 
patients (20%) were treated by dermatologists in non-hospital settings; 10 of these patients had type I infection 
and one patient had type II infection. All patients treated in non-hospital settings received a one-drug regimen, 
and median treatment duration was 80 days (IQR: 42–113). The most frequent drug of choice was doxycycline 
(36.4%) and median treatment duration was 91 days (IQR: 61–126). Outcome was classified as improved for 10 
patients and 1 patient was classified as failed.
The majority of patients treated in hospital settings was diagnosed with type I infection (61.9%). Of those with 
type I infection, 10 patients (38.5%) received a one-drug treatment. Among all patients treated in hospital set-
tings, 18 (43.9%) received a two-drug backbone regime and the overall median treatment duration was 123 days 
(IQR 84–244). The most commonly used combination in the 2, 3, and 4 drug backbone regimes were rifampicin 
and clarithromycin (38.9%).
Overall superficial infection (type I and type II) accounted for 92.5% of the cases, with a median treatment 
time of 110 days (IQR: 64–183). Fifty-one percent received a one drug regime and doxycycline was the most com-
mon drug prescribed (40%). The median treatment duration was 87 days (IQR: 42–130).
Among patients with deep tissue infection (type III and type IV), median time of treatment was 240 days 
(IQR: 50–284). They all received a treatment regime of at least 2 drugs, clarithromycin and ethambutol were 
included in all these treatment regimes.
Treatment outcome. The majority of the patients (75.5%) were classified as improved at treatment termi-
nation. Four patients were classified as improved with morbidity, two of these patients had type IV infection, and 
one patient had a finger amputated. The other patient received immunosuppressive therapy and had extensive 
scar tissue related to the sites of infection. The last two patients had type I infection; one of these patients was 
diagnosed with inflammatory bowel disease and received immunosuppressive therapy. At treatment termination, 
both patients were described having moderate scar tissue related to the site of infection.
Only 3 patients (5.7%) were classified as failed. In this group, two patients were diagnosed with rheumatoid 
arthritis and received immunosuppressive therapy at time of diagnosis. The first patient was treated for a type III 
infection for more than 5 years, treatment was discontinued several times, but the patient quickly showed signs 
of relapse, the patient was still receiving treatment as the study was concluded. The second patient was diagnosed 
with type I infection and was treated for 897 days but had signs of relapse at follow-up. The last patient had type II 
infection, was not immunocompromised, received a one drug regimen for 15 days and at the last visit the lesions 
were described as slightly improved and still visible.
Discussion
In this nationwide study, we reported 55 cases of culture confirmed M. marinum infections during a 13-year 
period. Infections with M. marinum are rare and related to aquatic exposure in Denmark. There is a long delay in 
diagnosis, but treatment outcome is overall good. However, severe manifestation of infection may be correlated 
with long treatment duration and need of surgery and sequelae.
More than 90% of the patients reported aquatic exposure. This is in consensus with the fact that M. marinum 
has been isolated from marine animals, fresh and saltwater2. The most common risk factor identified was fish tank 
maintenance, yet the incidence of M. marinum infections among owners of fish tanks is unknown. The last survey 
Figure 1. Incidence rate per 100 000 person years of M. marinum infection in Denmark with 95% confidence 
intervals. The population was defined as contributing to 1 person year per resident per year in the incidence rate 
analyses.
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in Denmark regarding pet owners was completed in 2000 and reported that 80.000 families own fish tanks20 this 
is less than 2% of families in Denmark. This indicates that the incidence of M. marinum infection among fish tank 
owners in Denmark is very low. However, there has been reported an increase in number of families (10%) own-
ing fish tanks in other countries2, which has been correlated to an increase in incidence of M. marinum infections 
during the last decade1. Yet, we were not able to identify a significant increase in the incidence rate of M. marinum 
infections in Denmark.
One patient in our study reported swimming pool as the sole known exposure. Before chlorination of swim-
ming pools, several outbreaks of M. marinum infections caused by swimming in pools were reported in the 
literature21,22. Today, this is an unusual mode of transmission. Outbreaks of M. marinum have been reported in 
fish farms8 and fish markets during the last decade6. In our study, there were no clustered reports of M. marinum 
cases, hence no suspicion of an outbreak.
The majority of the patients in this study reported location of infection corresponding to upper extremities 
(92.5%). This correlates with the most common exposure: maintenance of fish tanks, hence finger/hands are 
the most common exposed areas. Several previous studies have likewise reported upper extremities as the most 
common infection site1,8,10–14,23,24.
Median time from symptom onset to diagnosis in this patient group was 194 days, earlier studies have reported 
great variance in delay of diagnosis (median 35–105 days)1,6,24. Both patient delay and doctor’s delay contributed 
to the delay of diagnosis. The majority of patients had had symptoms for weeks to months before consulting a 
doctor. The doctor’s delay could be attributed to the rare nature of M. marinum infection and the fact that cutane-
ous elements can resemble a staphylococcus infection. M.marinum will typically be detected with a mycobacterial 
Variables Number (%)
Total 53a
Men 38 (71.7)
Age in years: median 49 (IQR: 36–59)
Immunocompromised 9 (17.0)
History of aquatic exposure:
Total 48 (90.6)
Fish tank 44 (83.0)b
Fishing 3 (5.7)
Handled fish/seafood 2 (3.8)
Swimming/diving 1 (1.9)
Severity of infection:
Type I 35 (66.0)
Type II 14 (26.4)
Type III 2 (3.8)
Type IV 2 (3.8)
Localization of infection:
fFinger/hand 47 (88.7)
iInvolved arm 17 (32.1)c
lLeg 3 (5.7)
Involved joints 2 (3.8)d
Diagnostic methods:
Microbiological:
Acid-fast bacilli stain positive 7 (13.2)
Culture from biopsy or aspiration or material from surgical procedures 53 (100)
Pathology examination:
Granulomatous inflammation 35 (66.0)e
No granulomatous inflammation or positive acid-fast bacilli stain 4 (7.6)
Imaging performed:
X-ray only 5 (9.4)
MRI 3 (5.7)f
PET-CT 3 (5.7)g
None 43 (81.1)
Table 1. Characteristics and diagnostic methods used in patients with M. marinum infection in Denmark. 
aTwo patients with missing medical records were left out of the analyses. bTwo patients reported exposure to fish 
tank and fishing. cFifteen patients had involvement of finger/hand and arm. dOne patient had involvement of 
joint and finger/hand and arm. eForty-two patients had histological examination performed. fThree patients had 
X-ray and MRI performed. gThree patients had X-ray and PET-CT performed, one patient had X-ray, MRI and 
PET-CT performed.
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culture performed at a lower temperature than usual. Unless the necessary information was lacking, all specimens 
from skin or from patients who had a suspected M. marinum infection were also cultured at a lower temperature. 
However, a delay in diagnosis was not significantly related to a poorer outcome in this study.
Our study consisted of patients with culture confirmed M. marinum infection, but only 13.2% had a posi-
tive AFB microscopy. Previous studies have also reported a low occurrence of positive AFB microscopy among 
patients with M. marinum infection (0–39%)6,8,11,12,14,24,25, indicating that a negative AFB microscopy cannot rule 
out the diagnosis of M. marinum infection and must be accompanied by culture.
Only 19% of patients had imagining performed. However more than 90% of our patients had type I or type 
II infection, which is compatible with superficial cutaneous infection. Therefore, in the majority of these cases 
there will not be an indication for imaging. Previous studies have shown a similar distribution of the severity of 
infection, hence M. marinum infection is more commonly a superficial infection that is limited to the skin. Most 
deep tissue infections with M. marinum have been reported as case studies in older and or immunocompromised 
patients1,18,26–28. This correlates with our results that only 4 patients (8%) had deep tissue infection and 2 of these 
patients received immunosuppressive therapy.
The results of this study revealed that 24 (45%) of the patients received a one-drug regimen. All of these 
patients had superficial cutaneous infection (type I: 80%, type II: 20%). Reported outcome was good; 88% of these 
patients were classified as improved and only one patient was classified as treatment failure at last contact. The 
remaining two patients in the group treated with a one-drug regimen were lost to follow-up.
Infections with M. marinum are rare, consequently there have not been any trials comparing treatment regi-
mens and the optimal combination of antibiotics and treatment duration remains unknown. In Denmark there 
is no national guideline regarding treatment of M. marinum infections. But according to the guidelines of the 
American Thoracic Society and the Infectious Disease Society of America, a combination of clarithromycin and 
ethambutol, with the addition of rifampicin for deep structure infection is preferred, and a one drug regimen is dis-
couraged29. However, earlier studies have described a successful outcome with a single drug regimen for superficial 
cutaneous infection8,10,15. One-hundred percent of the patients treated with a 3 or 4 drug backbone regime received 
Total
Number (%)
53
Backbone antibiotic regimena,b
One drug 25 (48.1)
Two drugs 18 (34.6)
Three drugs 8 (15.4)
Four drugs 1 (1.9)
Treatment duration in days, median (IQR):
Overall: 112 (64–203)
Type I 120 (83–143)
Type II 74 (30–180)
Type III 284 (284–284)
Type IV 145 (50–240)
Regimens including:
Rifampicin and ethambutol 176 (112–284)
Clarithromycin and ethambutol 123 (87–244)
Rifampicin, clarithromycin and ethambutol 176 (112–244)
Outcome:
Improved 40 (75.5)
Improved with morbidity 4 (7.5)
Failed 3 (5.7)
Lost to follow up 6 (11.3)
Outcome: “improved” for one drug regimen (n = 27) including:
Tetracyclines (n = 16)c 14 (87.5)d
Macrolides (n = 6)e 6 (100.0)
Outcome: “improved” for 2–4 drug regimen (n = 27) includingf
Rifampicin and ethambutol (n = 11) 7 (63.6)
Clarithromycin and ethambutol (n = 15) 9 (60.0)
Rifampicin, clarithromycin and ethambutol (n = 9) 5 (55.6)
NOT including clarithromycin and ethambutol (n = 12) 9 (75.0)
Table 2. Treatment of patients with M. marinum infection in Denmark. aThe antibiotic regimen used for 
the majority of the treatment period. bOne patient received multiple combinations of antibiotics; backbone 
therapy could not be assessed. cTen patients received doxycycline and 6 patients received tetracycline. dTwo 
patients were lost to follow up. eFive patients received clarithromycin and one patient received azithromycin. 
fClarithromycin was the only macrolide used in the 2–4 drug regimens.
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a combination of rifampicin, clarithromycin and ethambutol, however of the patients receiving a 2 drug backbone 
regimen only a third received clarithromycin and ethambutol. Notably, the outcome was not significant better in 
the group receiving clarithromycin and ethambutol. In our study, all patients with type III or type IV infection 
were treated with a combination of two drugs or more, including clarithromycin and ethambutol. When the study 
was completed, two of these patients were still on treatment. Both patients had been diagnosed with rheumatoid 
arthritis and received immunosuppressive therapy and had been treated for M. marinum infection for more than 
2 years. Furthermore, all patients on immunosuppressive therapy were treated longer than patients who did not 
receive immunosuppressive therapy. However, the overall outcome was good. In total, 66.6% of these patients were 
described as improved at treatment termination. This supports earlier studies, suggesting that immunocompro-
mised patients may need a prolonged multi-drug regimen when diagnosed with a M. marinum infection30.
The strengths of this study are the nationwide design and all cases are culture confirmed. In only 2 cases the 
patients’ medical records could not be obtained.
Our study has inherent limitations: the true incidence of M. marinum infections might be greater than esti-
mated in this study, as we included only patients with culture-confirmed M. marinum infections and patients 
treated based on a clinical diagnosis were left out.
Conclusion
M. marinum infections are rare and there is a long delay from symptom manifestation to diagnosis. The infection is 
highly related to aquatic exposure, which emphasizes that M. marinum should be a differential diagnose in patients 
with slow-developing cutaneous elements and relevant exposure. Prolonged therapy may be needed in patients 
receiving immunosuppressive therapy and severe sequelae are rare but often related to deep tissue infection.
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